ASCO: Survival Up With Patient-Reported Outcomes During CA Tx

Share this content:
ASCO: Survival Up With Patient-Reported Outcomes During CA Tx
ASCO: Survival Up With Patient-Reported Outcomes During CA Tx

MONDAY, June 5, 2017 (HealthDay News) -- A patient-reported outcome (PRO) intervention for symptom monitoring is associated with improved overall survival for patients treated with chemotherapy for metastatic solid tumors, according to a research letter published online June 4 in the Journal of the American Medical Association. The research was published to coincide with the annual meeting of the American Society of Clinical Oncology, held from June 2 to 6 in Chicago.

Ethan Basch, M.D., from the University of North Carolina at Chapel Hill, and colleagues examined overall survival associated with electronic patient-reported symptom monitoring versus usual care among patients initiating routine chemotherapy for metastatic solid tumors. A total of 766 participants were randomized to the usual care group or PRO group, assessed via a web-based PRO questionnaire platform. An e-mail alert was triggered to a clinical nurse when the PRO group participants reported a severe or worsening symptom.

Overall survival was assessed after 67 percent of the participants had died, at which time the median follow-up was seven years. The researchers found that the median overall survival was 31.2 and 26.0 months in the PRO and usual care groups, respectively (difference, five months; P = 0.03). The results remained significant in a multivariable model, with a hazard ratio of 0.83 (P = 0.04).

"Electronic patient-reported symptom monitoring may be considered for implementation as a part of high-quality cancer care," the authors write.

Two authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths